Imagination TV (OTC:IMTV) Stock, Quote.Headers.trade-ideas

Imagination TV Inc is an online media and entertainment company with a focus on the Music & Live Event industries.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACNNF

AEMD

AESE

AGHI

AIRG

AKER

AMCX

AMRH

AMRK

ANDR

APAAF

ATADF

BNKPF

BOSC

BRGO

CADMF

CFWFF

CHKIF

CLXT

CNGGF

CPPMF

CPYT

DELRF

DIALF

DLPN

DLUEY

DTNOF

ECIFY

EGRAF

EVLO

FDMF

FITX

GARB

GDRZF

GLOP

GMHLF

GNAL

GOHE

GRSO

GTBP

HAON

HENC

HGHAF

HHPHF

HVBTF

IDXG

IMBBY

IMTV

INAP

INDXF

INND

INNMF

IPIX

JBFCF

JBFCY

JWCAF

KBSF

KWBT

LKCO

LTBR

LUCRF

GLOBALIVE TECH INC by Globalive Technology Inc.

LVVEF

MCEP

MDTR

MFST

MREO

MRIN

MTFB

NIMU

NOHO

NRGMF

NWCI

OCGN

PHVAF

PMGYF

PPCLY

PRGX

PRLE

PTNYF

PXPP

PZRXQ

RCKHF

RLBD

RMHB

RVSDF

SCNNF

SITO

SNDL

SNOA

SPLIF

SQNS

Stocks That Hit 52-Week Lows On Tuesday

IMAGINATION TV INC by Imagination TV, Inc.

Imagination TV Inc

Offerings

YOSH

Yoshiharu Global  Filed For Offering Of Up To 400K Shares

Benchmark analyst Daniel Kurnos maintains Sinclair (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) with a Buy and raises the price target from $29 to $30.

Price Target

Analyst Ratings

SBGI

Benchmark Maintains Buy on Sinclair, Raises Price Target to $30

Leading private markets investment management firm Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) announced that it has been named to the S&amp;P MidCap 400 by S&amp;P Dow Jones Indices, effective before the open of trading today, Monday, September 23, 2024.&nbsp;
For more than 30 years, Hamilton Lane has been dedicated exclusively to private markets investing, providing innovative solutions to institutional and private wealth investors around the world. As of June 30, 2024, the firm had more than $940 billion in assets under management and supervision, composed of nearly $130 billion in discretionary assets – representing 11% year-over-year growth – and more than $810 billion in non-discretionary assets.&nbsp;
Hamilton Lane Co-CEO <a href="https://www.hamiltonlane.com/en-us/about/our-team/erik-hirsch">Erik Hirsch</a> commented: "The addition of our firm to the S&amp;P MidCap 400 Index represents a significant milestone in Hamilton Lane's 33-year growth story – a story that continues to evolve but that has always been driven by our focus on delivering for our clients. &nbsp;We have an exciting path forward, as we continue to lean into our culture of integrity, innovation and the pursuit of excellence, while adapting to meet the evolving needs of private markets investors of all sizes with new technology, new markets and new regions across the globe."

Government

Regulations

HLNE

Hamilton Lane Joins S&P MidCap 400, Marks Major Growth Milestone in Private Markets

<a href="https://pr.report/2vaa">Alta Global Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) ("Alta" or the "Company"), a pioneering technology company uniting passion and participation in global combat sports with a vision of converting 640 million fans to participants, announced its partnership with <a href="https://pr.report/2vab">UFC Gym Group</a> has the potential to deliver gross revenue of $7,000,000 per annum&#x2A; upon roll-out of UFC Gym's global gym footprint of over 150 gyms. The program will launch in California, scheduled to go on sale to members in September 2024. This represents Alta's first major enterprise partnership and will look to integrate Alta's innovative products and programs across UFC Gym's extensive network of global gyms.
&nbsp;
Nick Langton, Founder and CEO of Alta Global Group, commented, "This partnership with UFC Gym Group is a transformative milestone for Alta. By integrating our Warrior Training Program and mobile marketing platform into UFC Gym's global network, we're poised to significantly expand our reach while offering a unique pathway for UFC fans to experience the sport firsthand. UFC Gym is an ideal partner for us to deliver an unmatched training experience that not only elevates the gyms but also empowers participants. We're excited about the tremendous potential this collaboration holds for driving growth and deepening the connection between 640 million MMA fans and the sport."
Additional highlights of the partnership include:
Program Rollout: Alta will roll out its highly acclaimed 20-week Warrior Training Program across the United States and internationally. In the first year, these programs will be introduced in 15 locations across the US.
Revenue Opportunities: The Alta Warrior Training Program, which averages 24 participants per program, enables gyms to run up to two programs annually. Participants pay between $1,000 and $1,500 for the 20-week experience.
Mobile Marketing Platform: Furthermore, UFC Gym Group will utilize Alta's all-in-one mobile marketing platform, Hype, to enhance customer acquisition and retention across its network of over 150 gyms. Hype, powered by Alta, operates on a traditional Software-as-a-Service (SaaS) model.
Extensive opportunities for growth: Currently, UFC Gym Group boasts over 150 locations in 40 countries worldwide, including 80 in the United States, with hundreds of additional gyms in development.

Alta Global Partners With UFC Gym, Targets $7M Annual Revenue From Global Expansion

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrisaluslifesci.com%2F&amp;esheet=54124814&amp;newsitemid=20240919558761&amp;lan=en-US&amp;anchor=TriSalus+Life+Sciences%26%23174%3B%2C+Inc.&amp;index=1&amp;md5=99cfa17a1abb371957d4eef59928821a">TriSalus Life Sciences&#xAE;, Inc.</a> ("TriSalus" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model," in the peer-reviewed Journal of Vascular and Interventional Radiology. The article illustrates that the PEDD method via the TriNav Infusion System significantly improved delivery of glass microspheres (GM) with deeper penetration into liver tumors and the peritumoral tissue, when compared to delivery of GM with a conventional microcatheter in a transgenic (oncopig) model.
"This is another example of how our PEDD approach effectively tackles a significant challenge in cancer care by ensuring the selective and increased delivery of therapeutics to the tumor. This research advances and validates our understanding of the PEDD method, providing high-resolution evidence of enhanced delivery," said Bryan F. Cox, Ph.D., Chief of Research for TriSalus. "With both proximal and distal placements of the PEDD device, we observed significantly improved delivery of glass microspheres to the tumor, quantified on a millimeter scale. The strength of the proximal infusion data suggests an opportunity to selectively target multiple tumors simultaneously in patients with heavy disease burdens."
"These results contribute to the substantial and expanding body of pre-clinical and clinical evidence supporting the wide-ranging potential applicability of the PEDD approach," said Mary Szela, Chief Executive Officer and President of TriSalus. "Efficient delivery of therapeutics into tumor cells without causing harm to off-target normal tissue remains a real-world challenge in cancer care, and the PEDD approach aims to overcome this obstacle. This publication strengthens our current understanding that, regardless of placement of the technology, either lobar or selective infusions, the PEDD method increased glass microspheres delivery uptake compared to conventional microcatheters. The TriNav device signifies a potential breakthrough in delivering glass microspheres and other drugs into tumors in a highly controlled and targeted manner."
"This study shows the potential of PEDD method to address an unmet need in liver cancer therapy – achieving the same safety profile of selective Y90 treatment to those performed for more advanced diffuse disease using lobar injections. This study suggests that the use of PEDD method alters hemodynamics and the microenvironment in a manner resulting in higher concentrations of microspheres in the tumor compared to the adjacent liver parenchyma, thereby offering the ability to increase efficacy and improve safety. If further validated in human models, this may represent a significant advancement in the management of liver cancer," said Dr. Riad Salem, Chief of Interventional Radiology, and Professor of Radiology, Surgery, and Medicine in Chicago.
The research involved transgenic pigs (oncopigs) with induced liver tumors. These tumors were intra-arterially infused with fluorescently labeled GM. The PEDD method with the TriNav device was compared to the use of conventional microcatheter delivery in both lobar and selective infusions. Near-infrared (near IR) imaging was utilized to detect the GM fluorescent signal in tumors. The results showed significant increases in GM signal intensity in and around tumors after delivery with the PEDD method, with a 117% increase in tumor penetration with lobar infusions and a 39% increase with selective infusions compared to conventional delivery. Lobar PEDD delivery of GM to the tumor was statistically equivalent to conventional selective delivery (p=0.497).

TLSI

TriSalus PEDD Method Increases Microsphere Penetration in Liver Tumors, Study Highlights New Delivery Approach

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Progyny Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>)</h3>
<ul>
<li>On Sept. 19, the company said a client elected to exercise an option to terminate its services agreement with the company. The company's stock fell around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/PGNY">52-week low of $13.93</a>.</li>
<li>RSI Value: 26.50</li>
<li>PGNY Price Action: Shares of Progyny rose 1% to close at $16.62 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> latest PGNY news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="895" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171.png" alt="" class="wp-image-560811" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171-768x721.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<h3 class="wp-block-heading">Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Sept. 4, Indivior issued an update on Aelis Farma&#8217;s Phase 2B study with AEF0117 in participants with cannabis use disorder. It <a href="https://www.benzinga.com/quote/INDV">has a 52-week low</a> of $9.14.</li>
<li>RSI Value: 25.92</li>
<li>RELI Price Action: Shares of Indivior fell 2.1% to close at $9.48 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> trend in INDV stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172.png" alt="" class="wp-image-560812" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</h3>
<ul>
<li>On Sept. 17, Moderna announced that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.The vaccine targets the KP.2 variant of COVID-19. The company plans to begin delivery of the vaccine to the Public Health Agency of Canada shortly. "With the recent increase in COVID-19-infections, staying up to date with your COVID-19 vaccination remains one of the best ways to help protect yourself from severe illness," said Dr. Shehzad Iqbal, country medical director, Moderna Canada. The company's shares fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MRNA">low of $62.55</a>.</li>
<li>RSI Value: 28.17</li>
<li>MRNA Price Action: Shares of Moderna fell 3.4% to close at $65.69 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1">breakout in MRNA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173.png" alt="" class="wp-image-560813" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173-768x710.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
Read Next:<a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

INDV

MRNA

PGNY

Top 3 Health Care Stocks That May Explode This Month

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Forthofix.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=Orthofix+Medical+Inc&amp;index=1&amp;md5=f980520f95bd1a9234c20487cdf8b284">Orthofix Medical Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbonegrowththerapy.com%2Ftherapies%2Fspinal-fusion%2Fspinalstim-lumbar-fusion%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=SpinalStim&amp;index=2&amp;md5=c26f0cc0fb348022b3ce0b675596e790">SpinalStim</a>&#x2122; bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.
The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center.
During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand&#x2122; Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell&#x2122; Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips. Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fm6disc.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=M6-C&amp;index=3&amp;md5=0f2300dfde3b2d3c8390c084ccf90edc">M6-C</a>&#x2122; Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty.

OFIX

Orthofix Unveils New Spinal Fusion Products and Data, Highlighting Innovation at NASS Annual Meeting

Alibaba Group Holding&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) cloud computing services unit tapped&nbsp;Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to boost the&nbsp;autonomous driving&nbsp;experience for Chinese smart vehicle owners like Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>),&nbsp;Great Wall Motor Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GWLLY#OTC">GWLLY</a>),&nbsp;Geely Auto&#8217;s&nbsp;ZEEKR Intelligent Technology Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)&nbsp;and the EV unit of&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>).
China is currently grappling with U.S. advanced semiconductor sanctions, which have restricted its access to Nvidia and other chipmakers&#8217; sophisticated artificial intelligence chips.
The U.S. chip companies opposed the U.S. move, citing the importance of China as a key semiconductor market. Alibaba has also voiced how the embargo has affected its AI endeavors.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/09/40923879/chinas-ymtc-makes-strides-in-chip-production-substitutes-asml-lam-research-tech-as-us-sanctions-bite" rel="noreferrer noopener">China&#8217;s YMTC Makes Strides in Chip Production; Substitutes ASML, Lam Research Tech As US Sanctions Bite: Report</a>
Alibaba Cloud showcased a large multimodal model (LMM) solution for automotive applications that it co-developed with its intelligent cockpit solution provider Banma Network Technology and Nvidia at the&nbsp;Apsara Conference, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3279428/alibaba-nvidia-collaborate-advanced-autonomous-driving-solution-computing-services" rel="noreferrer noopener">reports</a>.
Alibaba Cloud integrated Qwen&#8217;s portfolio of proprietary large language models (LLMs) with Nvidia&#8217;s Drive AGX Orin platform for autonomous vehicles. The new LMM solution will enable in-car voice assistants to offer recommendations, and execute voice commands SCMP cites Alibaba Cloud.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17.png" alt="" class="wp-image-560553" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nvidia and Alibaba Cloud look to Qwen LLMs to Nvidia&#8217;s Drive Thor, a centralized car computing platform.
Last week, Alibaba kicked off its <a target="_blank" href="https://www.benzinga.com/government/24/09/40936014/whats-going-on-with-chinese-tech-stocks-like-alibaba-pdd-on-thursday" rel="noreferrer noopener">Aspara Conference 2024</a>, showcasing 100 open-source AI models catering to applications and sectors ranging from automobiles to gaming and science research.
Chinese e-commerce juggernaut Alibaba Group Holding&#8217;s stock has risen over 1% in the last 12 months as the weak domestic economy and geopolitical tensions bite.
Investors can gain exposure to the stock through the Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) and the Trust for Professional Managers ActivePassive International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APIE#NYSE">APIE</a>).
Price Actions: BABA stock is up 0.85% at $89.04 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40918150/alibaba-strikes-5-year-cloud-deal-with-indonesias-goto-delays-stake-divestment" target="_blank" rel="noreferrer noopener">Alibaba Strikes 5-Year Cloud Deal with Indonesia&#8217;s GoTo, Delays Stake Divestment</a></li>
</ul>
Photo by Fooksou Lamimo via Wikimedia Commons

Emerging Markets

Tech

Media

APIE

BABA

GWLLY

NVDA

PowerShares Golden Dragon Halter USX China Portfolio

XIACY

Alibaba Teams Up With Nvidia to Supercharge EVs for Chinese Automakers: Report

RBC Capital analyst Gregory Renza initiates coverage on CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Outperform rating and announces Price Target of $66.

Initiation

CGON

RBC Capital Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $66

<a href="https://www.globenewswire.com/Tracker?data=fTnauvHXrBinpqMkcNrU2jXyFxKpy_arXJzy_b5ASWO6l7AzfHZmmBhfNJU82qOIF0IRqYDITjpbTjTmYaz8lg==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure's investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.S., multi-center, open-label Phase I/IIa trial of AMT-191.
"This important designation highlights the need for new gene therapies like AMT-191 for patients with Fabry disease with the potential of delivering meaningful benefit given the suboptimal effectiveness of current chronic treatments," stated <a href="https://www.globenewswire.com/Tracker?data=XJHujD0zFsqCKj2AQYLx5YZE0M2jd1UjijpyNswg3uU3SriFCvwWI96vkEi8AA3le2sz_K36hMQhw9mjNc65v089QNwHSlUPjRhS5ybbM0ZoWv13dGsruJHJU5iG2D1r51IROOb0I1SREI2dhF2Cck4rSdmcC2GyFO4ZLtacqF9PhX4xHMVg625XkJYrftYl">Walid Abi-Saab, M.D., chief medical officer of uniQure</a>. "This designation supports our Phase I/IIa clinical trial and we look forward to rapidly generating clinical proof-of-concept data and providing initial data in 2025."
In patients with Fabry disease, a pathogenic variant in the galactosidase alpha (GLA) gene leads to α-galactosidase A (aGAL-A) enzyme deficiency, which in turn results in a progressive accumulation of lipids in multiple cell types, including kidney and heart cells, eventually resulting in a multi-system disorder. AMT-191 is a one-time intravenously administered investigational AAV5-based gene therapy that uses a proprietary, highly potent promoter to deliver a GLA transgene designed to target the liver to produce GLA protein.
The Phase I/IIa clinical trial of AMT-191 will be conducted in the United States. The multicenter, open-label trial consists of two cohorts with up to six adult male patients each: a low-dose cohort of 6x1013 gc/kg and a high-dose cohort of 3x1014 gc/kg delivered through a one-time intravenous infusion. Patients will continue to receive their regular enzyme replacement therapy until the criteria for withdrawal is met and will be followed for a period of 24 months. The trial will explore the safety, tolerability, and early signs of efficacy by measuring the expression of lysosomal enzyme aGLA-A. Additional details are available on <a href="https://www.globenewswire.com/Tracker?data=7KolP2h89egUHI8jH_Zo5bdDQZFzZM_38LjWTPDf3Kdw9gSQKRHs9DeKDUPU-daOSt9uPtk10WEjZA6W4qStkajilCQxvaD3HJzRrulXR-o=">www.clinicaltrials.gov</a> (NCT06270316).
The FDA's Orphan Drug Designation provides a special status for investigational drugs being developed for rare diseases considered to affect only up to 200,000 people in the United States. Orphan drug status provides certain incentives, including tax credits, grants and waiver of certain administrative fees for clinical trials as well as seven years of market exclusivity in the United States following drug approval.

QURE

FDA Grants Orphan Drug Status to uniQure's AMT-191, Aiming to Treat Fabry Disease

Biotech

Health Care

Stock Split

ORGS

Orgenesis Approves A 1-for-10 Reverse Stock Split Effective At 5:00 Pm Eastern Time On September 24

MIND Technology, Inc. ("MIND" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) announced today that its Seamap unit has received an order for a GunLink source controller amounting to approximately $5.1 million.&nbsp; Subsequent to July 31, 2024, the Company has received orders totaling approximately $7.9 million.
Mark Welker, Vice President of MIND and Seamap Managing Director, stated, "We are seeing strong demand for our GunLink source controllers. These most recent orders indicate the continuing demand across our family of source controller products. We expect to deliver a portion of these orders in this fiscal year; however, the majority will be delivered in our next fiscal year.&nbsp; In addition to the orders that we have in hand, we are pursuing a number of significant opportunities that we expect to bring to fruition in the coming weeks and months. We think our continuing backlog and pipeline of business bodes well for the balance of this fiscal year and next year as well."

MIND

MIND Technology's Seamap Unit Secures $5.1M GunLink Order, Expands Total to $7.9M

SKYE

Skye Bioscience Comments Regarding A Recent Announcement By Novo Nordisk On Phase 2a Topline Data With Monlunabant And, Reiterates Confidence In Its Nimacimab Clinical Development Plan, Says 16-week Top-line Weight Loss Data Validates Mechanism Of Action Targeting Peripheral CB1 Receptors

Federal Reserve

Minneapolis Fed President Kashkari Said Balance Of Risks Have Shifted Toward Risk Of Further Labor Market Weakening, Higher Unemployment; 50 BPS Rate Cut Was Right Decision, Reflects Progress On Inflation, Softening Of Labor Market

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today provided detailed virology data supporting previously communicated neutralization activity results, along with a genetic and structural analysis of past and present SARS-CoV-2 variant spike proteins, including the established molecular target of pemivibart.
As part of Invivyd's ongoing monitoring of antiviral activity, Invivyd contracts with LabCorp's Monogram Biosciences lab to provide independent, robust virology assessments in a consistent lineal chain that allows for consideration of potential changing pemivibart potency as SARS-CoV-2 evolves. Pemivibart potency against contemporary viruses KP.3.1.1 and LB.1 remains in-line with the totality of predominant variants dating back to 2022, including isolates identified during the conduct of the CANOPY Phase 3 clinical trial from late 2023 to early 2024. Data Table 1, below, provides relevant comparative values drawn from the PEMGARDA Healthcare Providers Fact Sheet.
"Quantitative neutralization assays exhibit marked intrinsic variability. Since discovery, pemivibart has exhibited impressively stable neutralization results across a wide range of SARS-CoV-2 variants, including and through contemporary variants tested," said Robert Allen, Ph.D., Chief Scientific Officer of Invivyd. "The values we observe thus far generally fall within the expected variability of the assay systems we employ."&nbsp;&nbsp;
Invivyd also provided an update to ongoing structural analysis showing no meaningful mutational change in the pemivibart binding site since the Omicron shift late in 2021. These data are presented in Figure 1 below. The pemivibart binding site is defined as a region of amino acid residues on the spike protein within 5 angstroms (5 Å) of the interaction between pemivibart and spike protein in a crystal structure and consists of 19 key amino acids. Invivyd's ongoing genetic and structural analyses of these residues provide the underlying biological rationale for the company's ongoing expectation for neutralization activity of pemivibart in the face of constant and convergent mutation in the SARS-CoV-2 spike protein. Analysis to date of all 19 amino acids presented below shows de minimis mutational change with ongoing stability to the binding site since the Omicron shift.
"To stay ahead of the curve, it is necessary to integrate data across multiple sources, including clinical and wastewater surveillance, as well as functional genomics. Invivyd's work over the last few years has achieved exactly that," said Kristian Andersen, Ph.D., a professor in the Department of Immunology and Microbiology at Scripps Research and member of Invivyd's scientific advisory board. "Continued surveillance of SARS-CoV-2 evolution is critically important to ensure that we can effectively counter the threat posed by the virus."

IVVD

Invivyd Shares New Data on Pemivibart's Neutralization of COVID Variants, Details Virus Evolution

U.S. index futures are modestly higher at the start of a new week as the rate cut euphoria fades and traders look ahead to the next key catalysts. The tech space could get a lift from <a href="https://www.benzinga.com/news/24/09/40975507/intels-stock-gains-in-pre-market-trading-following-reports-of-qualcomms-and-apollos-investment-offer">a potential lifeline for struggling Intel Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and traders may also look ahead to Micron Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) earnings report due later this week. FedEx Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) annual shareholder meeting and conference presentations by companies could also be on traders&#8217; radar.
A few Fed speeches and private sector activity data due on Monday will also be of interest to the market, which has had an atypically strong September. China followed up with more cuts on Monday as the country strives to bring the struggling economy back on track.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.15%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.06%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.32%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.15% to $569.09 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) climbed 0.27% to $483.06, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Week:
U.S. stocks recorded gains for the second straight week as the Fed&#8217;s 50 basis-point cut set the market on fire, although a session after the announcement. After a mixed start to the week, positive retail sales generated buying interest in the market on Tuesday. Sentiment soured on Wednesday despite the initial positive reaction to the rate cut and the major indices closed lower. 
Traders reacted with a lag to the rate cut, sending averages sharply higher on Thursday. The S&amp;P 500 Index and the Dow Jones Industrial Average scaled record highs in the session. Caution returned on Friday as the market closed the triple-witching session on a mixed note. The Dow built on its gains on Friday and ended at a new high.
&#8220;This might be a September rally to remember on Wall Street, as history is not on the side of September delivering many market rallies,&#8221; said fund manager Louis Navellier.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Weekly Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+1.50%</td>
<td>17,948.32</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+1.36%</td>
<td>5,702.55</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+1.62%</td>
<td>42,063.36</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+2.08%</td>
<td>2,227.89</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
The atypical September rally points to more gains ahead before the year ends, says Carson Group&#8217;s Chief Market Strategist Ryan Detrick. A new high for the S&amp;P 500 Index in September has meant an even better fourth quarter in the past, he said. The market has risen 19 out of 21 times and the average gain is nearly 5%, he said. If the new high was made in September, which also happens to be an election year, the fourth quarter is higher 100% of the time with an average gain of 6%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When the S&amp;P 500 makes a new high in September (like &#39;24) it appears Q4 does even better. In fact, higher 19 out of 21 times (90.4%) and up nearly 5% on avg. New highs in Sept of election year? Q4 higher 6 out of 6 and up nearly 6% on avg.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1837903370494820836?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The S&amp;P 500 Index, which closed Friday&#8217;s session, just shy of an all-time high, is now above year-end price predictions of 70% of Wall Street analysts. This has rendered S&amp;P valuation slightly higher than the average number for the past five and past 10 years, FactSet data showed.
JPMorgan Global Investment Strategist&nbsp;Sarah Stillpass&nbsp;said in a report the September rate cut could bode well for equities. Since 1980, five of the 10 best years for the S&amp;P 500 happened when the Fed was cutting rates without a recession, she said. She also noted that the Fed has cut rates 12 times when the S&amp;P 500 was within 1% of its all-time high such as the current year. The market was higher one year later all 12 times, with a median return of 15%, she added.
See also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a>
Upcoming Economic Data:
A slew of Fed speeches and the core personal consumption expenditure index, which is part of the personal income and spending report, are the key data the market will likely look forward to in the unfolding week. Traders may also keep a close eye on the weekly jobless claims data, flash private sector activity readings from S&amp;P Global, a consumer confidence reading, the August durables goods orders data and a couple of housing market readings.
On Monday, Atlanta Fed President Raphael Bostic is scheduled to speak at 8 a.m. EDT, followed by Chicago Fed President Austan Goolsbee at 10:15 a.m. EDT and Minneapolis Fed President Neel Kashkari&nbsp;at 1 p.m. EDT.
S&amp;P Global will release its flash manufacturing and service sector purchasing managers&#8217; indices for September at 9:45 a.m. EDT. Economists, on average, expect the manufacturing purchasing managers&#8217; index to rise from 47.9 in August to 48.4 in September, suggesting the sector continued to contract. The service sector PMI is widely expected to hold steady at 55.4 compared to August&#8217;s 55.7.
The Treasury will auction three- and six-month notes at 11:30 a.m. EDT.
Stocks In Focus:
<ul>
<li>Intel rose about 3% <a href="https://www.benzinga.com/premarket">in premarket trading</a> amid reports that Apollo Global Management seeks to invest $5 billion in the chipmaker in return for an equity stake in the company. Incidentally, Qualcomm, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is rumored to be interested in buying Intel.</li>
<li>Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally is sending crypto-linked stocks higher on Monday.</li>
<li>Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) fell over 1.60% following a negative analyst action. The company will be added to the S&amp;P 500 Index, along with Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) and Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>).</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is due to <a href="https://www.benzinga.com/calendars/earnings">announce its quarterly results after the market closes.</a></li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil and gold futures are modestly higher, with the latter trading near record territory. Bitcoin has gone past the $63.5K level. The 10-year Treasury note yield rose 1.1 points to 3.739%.
The Asian markets closed on a lackluster note, although the Japanese market remained closed for a public holiday. The People&#8217;s Bank of China announced a cut to its 14-day reverse repurchase rate, following up with the downward adjustments that began in July. Chinese central bank governor Pan Gongsheng will hold a press conference Tuesday on financial support for economic development, alongside two other officials, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-23/china-announces-another-rate-cut-as-growth-slowdown-worsens">reported.</a>
European stocks also showed tentativeness as domestic traders digested weak private sector activity data from the region.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40974885/s-p-500-outpaces-wall-street-projections-as-year-end-nears-will-the-rally-hold">S&amp;P 500 Outpaces Wall Street Projections As Year-End Nears: Will The Rally Hold?</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Futures

Previews

Economics

$BTC

DELL

ERIE

INTC

PLTR

QCOM

Wall Street Eyes Modestly Positive Start As Atypical September Rally Generates Positive Sentiment, China Cuts Rate: Intel, Palantir, Bitcoin Make Huge Moves

<ul>
<li>Riot has agreed to withdraw its June 24, 2024 requisition, as amended, and to accept customary standstill provisions through the Bitfarms 2026 Annual Meeting, with certain exceptions.</li>
<li>The Company has provided Riot with certain rights (subject to certain exceptions) to purchase shares of the Company provided Riot holds&nbsp;15%&nbsp;or more of the outstanding common shares of the Company.</li>
</ul>

Management

BITF

RIOT

Bitfarms, Riot Platforms Enter Settlement Agreement In Advance Of Special Meeting; Andrés Finkielsztain Has Stepped Down From Bitfarms' Board, Amy Freedman To Join Board

ALKS

Alkermes Announced Plans To Present Clinical Data From Its Phase 1B Study Of ALKS 2680 In Patients With Narcolepsy Type 2 And Idiopathic Hypersomnia At The European Sleep Research Society Congress, Sleep Europe 2024

MoffettNathanson analyst Michael Nathanson initiates coverage on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Neutral rating and announces Price Target of $100.

MoffettNathanson Initiates Coverage On Trade Desk with Neutral Rating, Announces Price Target of $100

<a href="https://www.globenewswire.com/Tracker?data=r4RuL-g8BiKVZqLRnMl8EGgAMp3MEvcuP1lhTYpiuoJgsZ1jahk_eeysIWLnQ1bAlIACdbq5BXPKTE0CscTH9fs6bHnXyXzwYWhIPkSFsL0=">Black Diamond Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC).
"Patients often become resistant to osimertinib with the emergence of on-target resistance EGFR mutations," said Sergey Yurasov, M.D., Chief Medical Officer of Black Diamond Therapeutics. "Our preliminary Phase 2 data demonstrate the potential of BDTX-1535 to deliver durable responses for these patients."
"Patients with recurrent EGFRm NSCLC have few treatment options, with chemotherapy delivering limited benefit and significant toxicity, and initial Phase 2 data with BDTX-1535 look quite promising," said Danny Nguyen, M.D., <a href="https://www.globenewswire.com/Tracker?data=vlr3UZ7jREPq-nVuV_0_0C88uBRItoG_u2Pds2FLZhl6OdG7j4DTPUFysQY2y_LIjwyzqAqfOfpni53hE75snJRWUiN0k0RirbHBhXGxPKYSET-VNVVUwbCm2cnWyEzenhj0xWJvWFDh1oHU2wzxnXLBK7T4WBCokjmhe7dQL7lQDcWhMG63hpBMKrSRhrsiyEiYvQrw6wRSj8xyaeufaSI2us8FlQDhdtCYWaPgkus=">Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research at City of Hope</a>. "There is a significant unmet medical need for an effective and well-tolerated oral therapy for patients who progress on osimertinib, as well as newly diagnosed patients with non-classical mutations."
Phase 2 preliminary data overview:
The phase 2 trial began in August of 2023, and enrolled relapsed/refractory patients with non-classical EGFR mutations (NCMs) (Cohort 1) and those with C797S resistance mutations (Cohort 2). Safety assessment and dose selection were based upon the first 40 patients randomized to receive BDTX-1535 once daily at either 100 mg or 200 mg across both Cohorts. Preliminary response rate and durability were assessed in 27 patients at 200 mg with an August 17, 2024, data cutoff, including 22 response-evaluable patients who met protocol eligibility criteria.
Key takeaways:
<ul>
<li>200 mg daily selected for pivotal clinical development. Dose selection was based primarily on pharmacokinetics, safety and tolerability data from 20 patients at 100 mg, and 20 patients at 200 mg.</li>
<li>Favorable tolerability profile at 200 mg, consistent with prior BDTX-1535 clinical data. The majority of adverse events were mild or moderate, and no new safety signals were observed. The most common on-target treatment-related adverse events were rash (70%) and diarrhea (35%). There were 2 cases of grade 3 rash, and no reported cases of grade 4 rash or grade 3/4 diarrhea.</li>
<li>Preliminary objective response rate (ORR) of 42% achieved in 19 patients. For the 22 response-evaluable patients, the preliminary ORR was 36%. Nineteen of these 22 patients expressed known osimertinib resistance mutations: either C797S or P-loop alpha-C helix compressing (PACC, a major subset of NCMs). Of these 19 patients, 8 achieved a response (42%): 5 with a confirmed partial response (PR), including 1 patient who converted from a PR to an unconfirmed complete response (CR) at 8 months (and awaits confirmatory scan); and 3 with an unconfirmed PR at first scan and awaiting a confirmatory scan. An additional 9 patients experienced stable disease.</li>
<li>Encouraging durability observed, with duration of response (DOR) of approximately 8 months or more for first 3 patients with PR; 14 of 19 patients remain on therapy. Mean follow-up time is 4.7 months.</li>
</ul>
"We are pleased to see significant Phase 2 clinical activity and tolerability that are consistent with our Phase 1 results," said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics. "We believe that the activity observed in the recurrent setting can translate to robust clinical benefit in the first-line setting, and we look forward to sharing data from our trial in newly diagnosed patients in Q1 2025."
Black Diamond continues to enroll patients in the second- and third-line cohorts, as well as in the first-line setting for patients with non-classical EGFR mutations. In Q1 2025, the Company expects to disclose initial results from the first-line cohort and to outline potential registrational paths in the recurrent setting based on FDA feedback.

BDTX

Black Diamond Reports Phase 2 Results for BDTX-1535 in Lung Cancer, Targets FDA Approval Path

Imagination TV

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Imagination TV

Imagination TV (IMTV) Forecast

Imagination TV (OTC:IMTV) Stock, Quote.Headers.trade-ideas